MALAT1 sponges miR-106b-5p to promote the invasion and metastasis of colorectal cancer via SLAIN2 enhanced microtubules mobility

Meng Zhuanga,1, Senlin Zhab,c,d,1, Zheng Jianga,1, Song Wange, Peng Sun e, Jichuan Quana, Dongwang Yan a,a,⁎, Xishan Wang a,a

a Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
b Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
c Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
d Department of General Surgery, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
e Department of Colorectal Surgery, the Second Afliated Hospital of Harbin Medical University, Harbin, China

Article history:
Received 29 September 2018
Received in revised form 6 December 2018
Accepted 20 December 2018
Available online 21 February 2019

Background: The low expression of miR93/25 (members of miR-106b–25 cluster) promoted the invasion and metastasis of colon cancer cells, which predicted poor survival. However, the role of miR-106b-5p, the member of miR-106b–25 cluster, in colorectal cancer (CRC) remains unclear.

Methods: Bioinformatics methods were used to predict the potential pairs of lncRNA-miRNA-mRNA. In situ hybridization and qPCR were used to evaluate the expression of MALAT1 and miR-106b-5p in the paraffin-embedded normal and CRC tissues. Kaplan–Meier analysis with the log-rank test was used for survival analyses. Immunohistochemistry staining was applied to investigate the expression of SLAIN2. Fluorescence recovery after photobleaching assay was applied to observe the microtubule (MT) mobility. In vitro and in vivo invasion and metastasis assays were used to explore the function of MALAT1/miR-106b-5p/SLAIN2 in the progression of CRC.

Findings: miR-106b-5p was identified as a suppressor in CRC. Functionally, ectopic or silencing the expression of miR-106b-5p inhibited or promoted the invasion and metastasis of CRC cells in vitro and in vivo. The long non-coding RNA MALAT1 regulated the miR-106b-5p expression and further mediated the mobility of SLAIN2-related MTs by functioning as a competing endogenous RNA in vitro and in vivo, which resulted in the progression of CRC. Clinically, low miR-106b-5p expression predicted poor survival of CRC patients, especially in combination with high MALAT1/SLAIN2 expression.

Interpretation: miR-106b-5p served as a suppressor in combination with MALAT1/miR-106b-5p/SLAIN2, which might be a group of potential prognostic biomarkers in the prognosis of CRC.

Fund: This work was supported by National Program Project for Precision Medicine in National Research and Development Plan of China (2016YFC0905300), National Natural Science Foundation of China (81572930), National Key Key Research and Development Program of the Ministry of Science and Technology of China (2016YFC0905303, 2016YFC1103200), Beijing Science and Technology Program (D17110002617004), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018PT32012), CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-1-001), Incentive Fund for Academic Leaders of Oncology Hospital, Chinese Academy of Medical Sciences (RC2016003), and Beijing Hope Run Special Fund from Cancer Foundation of China (LC2017A19). The project of Shanghai Jiaotong University (YG2017QN30).

© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths worldwide [1], primarily originating from tumor metastasis [2], which is known to be involved in multi-genes and processes [3]. The aberrant regulation of oncogenes and suppressors play critical roles in the progressive cancers. Although several oncogenes or suppressors have
Research in context

Evidence before this study

CRC is the fourth leading cause of cancer-related deaths worldwide, which mainly resulted from tumor metastasis. The discovery of metastasis-associated markers and elucidating the mechanisms underlying the invasion and metastasis of CRC is urgently needed. Previous studies reported that the low expression of miR93/25 (members of miR-106b 25 cluster) promoted the invasion and metastasis of colon cancer cells, which predicted poor survival. However, as the member of miR-106b -25 cluster, the role of miR-106b-5p in the metastasis of CRC is yet to be clarified.

Added value of this study

The in vivo and in vitro experiments identified miR-106b-5p as a suppressor, and MALAT1/miR-106b-5p/SLAIN2 axis played a significant role in promoting CRC.

Implications of all the available evidence

The MALAT1/miR-106b-5p/SLAIN2 axis consists of a group of potential prognostic and promising diagnostic biomarkers in the progression of CRC.

been reported to guide the postoperative adjuvant chemotherapy, approximately 50% of CRC patients suffer from metastasis after the operation. Thus, identifying new prognostic markers and the mechanisms underlying the invasion and metastasis of CRC is an urgent requirement.

MicroRNAs (miRNAs, 18–24 nucleotides) are small non-coding RNAs that suppress the expression of targeted genes via binding to the 3-untranslated regions (3’UTRs) and regulate the progression of cancer [4]. Previously, we reported that as members of the miR-106b ~25 cluster, miR25and miR93 were downregulated in colon cancer and the low expression of miR93/25 promoted the invasiveness and metastasis of colon cancer cells [5]. Similarly, miR-106b-5p, also as the member of miR-106b ~25 cluster, is overexpressed in various chemo/radioresistant cancers, including clear cell renal cell carcinoma (ccRCC) and CRC. Furthermore, miR-106b-5p overexpression induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer [6]. Moreover, in ccRCC, characterized by exceptionally high resistance to radiation and chemotherapy, miR-106b-5p promotes renal cell carcinoma aggressiveness and stem-cell-like phenotype by activating Wnt/β-catenin signaling [7]. In addition, miR-106b-5p was found to be upregulated in ccRCC patients, and by inhibiting the function of the TRIM8 protein, the tumor suppressor activity of p53 is prevented, thereby enhancing the N-Myc pathway [8]. Thus, the miR-106b-5p might exert a dual role as a tumor suppressor or as an oncogene, thereby requiring further exploration of its roles in CRC.

Recently, accumulating evidence has shown that long non-coding RNAs (lncRNAs) are involved in cancer metastasis as competing endogenous RNAs (ceRNAs), followed by sponging and inhibiting the expression of miRNAs expression that activates the downstream targets [9]. Typically, the lncRNAs are longer than 200 nucleotides and lack the protein-coding functions. In addition, lncRNAs are known to be involved in a series of biological processes, such as chromatin modification, genomic imprinting, and the regulation of transcription and post-transcription [10]. In colon cancer, IncRNA HNF1A-AS1-mediated repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression by functioning as a ceRNA [11]. Linc00152 functions as a ceRNA that confers oxaliplatin resistance with prognostic values in colon cancer [12]. In renal cancer, exposure-transmitted IncARSR promotes sunitinib resistance by acting as a ceRNA [13]. Therefore, the ce-lncRNAs that are involved in the progression of CRC are promising prognostic factors in the disease. Whether miR106b-5p is regulated by lncRNAs via ceRNA roles also need further exploration.

In the present study, we demonstrated that 1) miR-106b-5p has a lower expression in stage IV than in stage I-II in CRC tissues; 2) low miR-106b-5p indicated a short survival in CRC patients; 3) MALAT1 sponges miR-106b-5p to promote the invasion and metastasis of CRC via SLAIN2-enhanced mobility of the MTs; 4) MALAT1/miR-106b-5p-mediated SLAIN2 overexpression predicted the poor survival for CRC patients. The current data clarified the sponging role of MALAT1/miR-106b-5p in CRC metastasis, and thus, might provide novel prognostic factors for CRC metastasis.

2. Results

2.1. Low expression of miR-106b-5p is positively correlated to tumor progression and predicts poor survival in CRC patients

In order to understand the role of miR-106b-5p in CRC, we analyzed the expression of miR-106b-5p in CRC in The Cancer Genome Atlas (TCGA) dataset. The level of miR-106b was significantly decreased in tumor tissues \((n = 340)\) as compared to normal tissues \((n = 11)\) (Fig. S1a). Subsequently, we assessed the level of miR-106b-5p in 95 pairs of CRC and normal samples obtained from Shanghai General Hospital and found that the expression was significantly lower in the tumor than that in the paired normal tissues (Fig. 1a). Furthermore, 52/95 patients were diagnosed as stage I-II, and the remaining 43 were diagnosed as stage III-IV according to the American Joint Committee on Cancer (AJCC). Based on the relapse, the 95 cases were also divided into two groups: relapse and non-relapse groups. Interestingly, qPCR showed that miR-106b-5p expression was much higher in both stage I-II \((8.05 \pm 2.06)\) and non-relapse group \((8.02 \pm 1.95)\) as compared to stage III-IV \((6.81 \pm 1.42)\) and relapse groups \((6.57 \pm 1.40)\) (Fig. 1b and c). Interestingly, the correlation between the clinicopathological parameters of the 95 CRC patients and miR-106b-5p expression revealed that the expression of miR-106b-5p was negatively associated with lymph node metastasis, distant metastasis, and tumor relapse (Table S1). These results indicated that low miR-106b-5p might be associated with CRC metastasis and relapse.

Next, Kaplan–Meier analysis with the log-rank test on the overall survival (OS) of the tumor, using the TCGA dataset, showed that low miR-106b-5p predicted a poor OS in CRC patients (Fig. S1b). Similarly, low miR-106b-5p also showed a poor OS and recurrence-free survival (RFS) in 95 CRC patients of Shanghai General Hospital dataset (Fig. 1d and e). Moreover, miR-106b-5p expression only affected the OS of the relapse group but not that of the non-relapse group (Fig. 1f and g). Taken together, these results indicated that low miR-106b-5p predicted the metastasis of CRC and poor prognosis.

2.2. Knockdown of miR-106b-5p promotes CRC invasion in vitro and in vivo

To explore the biological roles of miR-106b-5p in CRC progression, we analyzed the expression of miR-106b-5p in seven CRC cell lines (Caco2, HT-29, SW480, SW620, RKO, HCT-8, and LoVo) and one normal colon epithelial cell (NCM 460). As shown in Fig. S2a, the level of miR-106b-5p was lower in CRC cells than that in NCM 460 cells, and HCT-8 showed the lowest miR-106b-5p level, while SW480 presented a relatively high miR-106b-5p level; hence, these cells were selected for the following study (Fig. S2a). Subsequently, the mimics and inhibitors of miRNA-106b-5p were used to upregulate or knockdown miR-106b-5p in CRC cells, respectively (Fig. S2b and c). \(P < .01\) for both, Student’s t-test). Then, transwell assay was performed to measure the effects of miR-106b-5p on the CRC cells’ migratory (without Matrigel) and invasiveness (with Matrigel) capacities. We found that the knockdown or overexpression of miR-106b-5p significantly increased or decreased
the migratory and invasive capacities of SW480 or HCT-8 cells, respectively (Fig. 2a–d, both \( P < .05 \), Student’s \( t \)-test). These data demonstrated that the low expression of miR-106b-5p promoted the migration and invasion of CRC cells in vitro.

The liver metastasis of CRC is the most common metastasis in vivo. Thus, we performed an in vivo assay to investigate the effects of miR-106b-5p on tumor liver metastasis by injecting miR-106b-5p-silenced SW480 and miR-106b-5p-overexpressed HCT-8 cells as well as their controls into the tail veins of nude mice. Subsequently, ultrasoundography was used to monitor the liver metastasis for three weeks and continually up to week 9 (Fig. 2e, left panel). Furthermore, hematoxylin-eosin (HE) staining was performed to count the number of tumor colonies in mice liver samples (Fig. 2e, right panel). The knockdown or overexpression of miR-106b-5p gave rise to a significant difference of colony number in the liver as compared to the controls in nude mice, respectively (Fig. 2f, both \( P < .05 \), Student’s \( t \)-test). Taken together, these data further indicated that low miR-106b-5p expression also induced the invasion and metastasis of CRC cells in vivo.

2.3. MALAT1 functions as a ceRNA by sponging miR-106b-5p

Long non-coding RNAs are identified as critical regulators in tumor genesis and metastasis. Accumulating evidence demonstrated that lncRNAs regulate miRNA and mRNA expression through competitively sponging miRNAs. To predict the potential lncRNAs that regulate miR-106b-5p, we selected the pairs of lncRNA-miRNA that were supported by at least three algorithms from StarBase and also filtered the pairs of lncRNA-miRNA from miRcode database. Next, we selected 16 lncRNAs from both public databases as the potential upstream regulators (Table S2). Among the 16 candidates, 4 lncRNAs (HOTAIR, MALAT1, XIST, and ZNRD1-AS1) have been widely reported to be cancer-related lncRNAs, which might be associated with miR-106b-5p. Furthermore, we analyzed these four lncRNAs in CRC tissues to investigate whether they could regulate miR-106b-5p. qPCR was used to analyze the level of these four lncRNAs in 20 pairs of normal and CRC tissues. We found that 3/4 lncRNAs have an elevated expression in the CRC samples as compared to the normal. The fold-change in the expression of four lncRNAs (HOTAIR, MALAT1, XIST, and ZNRD1-AS1) in CRC and normal tissues were 3.05, 3.46, 1.47, and 2.09, respectively (Fig. S3a). Strikingly, the level of MALAT1 in cases of stage III-IV was much higher than that of stage I-II, while HOTAIR did not show this difference (Fig. S3b). MALAT1 may be more closely related to CRC metastasis than HOTAIR. Then, we evaluated MALAT1 expression in eight cell lines (Fig. S3c). The further correlation analysis indicated that MALAT1 expression was negatively associated with miR-106b-5p expression (Fig. S3d). These results suggested that expression of MALAT1 was associated with miR-106b-5p level and MALAT1 may be a potential regulator of miR-106b-5p in CRC.

In addition, SW480 and HCT8 cells were selected to establish the MALAT1-overexpression and knockdown cells (Fig. S3e–f).
bioinformatics analysis showed that MALAT1 contains a binding site of miR-106b-5p (Fig. 3a). We further mutated the binding sites of MALAT1 and miR-106b-5p, synthesizing the MALAT1 mut and miR-106b-5p mut plasmids. Also, the constructs containing MALAT1 (wild-type or mutant type) transcripts combined with the MS2 binding site were generated (Fig. 3b) and co-transfected into CRC cells with a construct containing MS2-binding protein (MS2bp, binds to the MS2 binding site) and GFP. An anti-GFP RNA immunoprecipitation (RIP) assay was performed, and the results showed that miR-106b-5p was only enriched in wild-type MALAT1, while the enrichment caused by mut MALAT1 was not significant as compared to the MS2 control (Fig. 3c). These results revealed that miR-106b-5p specifically binds to MALAT1. To further verify the correlation between miR-106b-5p and MALAT1, the RNA pull-down assay revealed that miR-106b-5p could be pulled down by biotin-labeled wild-type MALAT1. Also, MALAT1 could be pulled down by biotin-labeled wild-type miR-106b-5p, while the mutation in MALAT1 and miR-106b-5p resulted in the failure of pulldown (Fig. 3d and e). These data validated the binding roles between miR-106b-5p and MALAT1 in CRC cells.

Subsequently, a luciferase reporter construct containing MALAT1 (wild-type or miR-106b-5p binding site mutated type) was generated and co-transfected into SW480 cells or HCT-8 cells with miR-106b-5p inhibitor or miR-106b-5p mimics, respectively. Moreover, the luciferase assay showed that knockdown or overexpression of miR-106b-5p enhanced or inhibited the luciferase activity of wild-type MALAT1 but it does not affect the mutated type of MALAT1 (Fig. 3f and g). AGO2 is essential in miRNA-induced posttranscriptional repression or degradation of RNA to form an RNA-induced silencing complex (RISC) combined with the miRNA targets [14], which was confirmed with an anti-AGO2 RIP assay. Endogenous MALAT1 enrichment was decreased or increased after knockdown or overexpression of miR-106b-5p, which was not altered with the transfection of mut-miR-106b-5p (Fig. 3h and i). These results indicated that MALAT1 was recruited to AGO2-related miR-106b-5p-induced silencing complexes, thereby suggesting that MALAT1 interacts with miR-106b-5p.

To further elucidate the correlation between MALAT1 and miR-106b-5p, CRC cells were transfected with MALAT1 overexpression plasmids or shMALAT1 (Fig. S3e and f). The qPCR assay demonstrated that miR-106b-5p expression was reduced or upregulated in MALAT1-overexpressed SW480 or MALAT1-silenced HCT-8 cells but not changed in MALAT1-mut-transfected SW480 cells (Fig. 3j and k). Moreover, MALAT1 expression was negatively correlated with miR-106b-5p expression in 95 CRC tissues (Fig. 3l). RNA fluorescence in situ hybridization (FISH) assay was performed for their cellular localization. Even though MALAT1 is reported to be located in the nucleus, our results revealed MALAT1 and miR-106b-5p were highly enriched in the cytoplasm of CRC cells (Fig. S3g). Together, these data indicated that MALAT1 sponges miR-106b-5p and might function as ceRNA in CRC.

2.4. MALAT1 regulates the expression of SLAIN2 through competitive interaction with miR-106b-5p

To confirm the target gene of miR-106b-5p, we analyzed five miRNA datasets and predicted nine candidates that existed in all these five
miRNA datasets (Fig. 4a). miR-106b-5p mimics were transfected into HCT-8 cells, followed with a qPCR analysis of the nine targets. As shown in Fig. S4a, SLAIN2 was the most significantly downregulated gene. Furthermore, we evaluated the expression of SLAIN2 mRNA in eight cell lines (Fig. S4b), and the correlation analysis showed that SLAIN2 was negatively associated with miR-106b-5p (Fig. S4c). Then, we established the luciferase reporter construct containing wild-type or mutant SLAIN 3'UTR (Fig. 4b). Also, we synthesized the mut-miR-106b-5p with the bases paired with mut-SLAIN2 3'UTR (Fig. 4b). The luciferase activity was significantly increased or decreased after treatment with miR-106b-5p inhibitor or mimics in a dose-dependent manner (Fig. 4c). Additionally, the luciferase activity of wild-type, but not the mutant type, SLAIN2 3'UTR could be enhanced or reduced by miR-106b-5p inhibitor or mimics (Fig. 4d and e). However, mut-miR-106b-5p could attenuate the luciferase activity of mutant SLAIN2 3'UTR (Fig. 4e). Furthermore, both mRNA and protein levels of SLAIN2 were upregulated or downregulated after cells treated with miR-106b-5p inhibitor or mimics (Fig. 4f–i). These results confirmed that SLAIN2 is a target of miR-106b-5p and the 3'UTR can specifically bind miR-106b-5p in CRC cells.

Herein, we demonstrated that MALAT1 functioned as a ceRNA by sponging miR-106b-5p. Thus, we speculated whether MALAT1 regulated the SLAIN2 expression via sponging miR-106b-5p and promoted...
the progression of CRC. To verify this hypothesis, the luciferase assay was performed in CRC cells co-transfected with SLAIN2 3′UTR luciferase construct and MALAT1 or shMALAT1. The results showed that the overexpression of wild-type MALAT1, but not the mutant MALAT1, increased the luciferase activity of wild-type SLAIN2 3′UTR, and this promoted effect could be attenuated by miR-106b-5p mimics (Fig. 4k). Moreover, the luciferase activity of mutant SLAIN2 3′UTR could not be regulated by MALAT1 (Fig. 4k). Conversely, the depletion of MALAT1 could decrease the luciferase activity of wild-type SLAIN2 3′UTR, but not mutant SLAIN2 3′UTR, and this decreasing effect could be reversed by miR-106b-5p inhibitors (Fig. 4l). To further understand the regulation of MALAT1 on the endogenous SLAIN2 in CRC cells, we conducted qPCR and Western blot assays and evaluated the roles of MALAT1 on the mRNA and protein levels of SLAIN2. Consecutively, the ectopic expression of wild-type MALAT1, but not the mutant MALAT1, could upregulate the mRNA level of SLAIN2, which could be attenuated by transfecting with miR-106b-5p mimics (Fig. 4m). In contrast, the knockdown of MALAT1 downregulated the SLAIN2 mRNA expression, and miR-106b-5p inhibitor partially rescued this downregulation effect (Fig. 4n). In addition, the protein levels of SLAIN2 similar to that of the mRNA (Fig. 4o). These data demonstrated that MALAT1 regulated the expression of SLAIN2 through competitive interaction with miR-106b-5p and inhibiting the miR-106b-5p activity in CRC cells.

Clinically, we measured the expression of SLAIN2 in 95 CRC tissue samples using immunohistochemistry (IHC) staining and found that the expression was positively correlated with the TNM stage (Fig. 4p and Table S4). A subsequent correlation analysis of SLAIN2 IHC scores and MALAT1 and miR-106b-5p expression indicated that SLAIN2 expression was negatively associated with miR-106b-5p expression, while positively correlated with MALAT1 expression (Fig. 4q and r, both P < .05, Pearson’s correlation). Together, these results suggested that MALAT1 plays a critical role in the regulation of SLAIN2 expression by directly sponging miR-106b-5p in CRC.

2.5. MALAT1 sponges miR-106b-5p to promote the invasion and metastasis via SLAIN2-mediated the enhanced MTs mobility

Reportedly, SLAIN2 promotes mesenchymal cell invasion through the regulation of MTs growth [15]. MTs can modify cell morphology by regulating the polarity and adhesion of the cell, thereby resulting in pseudopod-based invasion [16]. The dynamics of MTs were associated with the migration and invasion of tumor cells [17]. Whether MALAT1 could mediate SLAIN2 involved in the enhancement of MTs mobility by sponging miR-106b-5p, followed by the invasion and metastasis of CRC is worth exploring. For further study, we firstly transfected Lv-SLAIN2 plasmid into SW480 cells to overexpress SLAIN2 (Fig. 5a) and performed transwell assays. Consequently, the overexpression of SLAIN2 increased the number of the migrated and invaded SW480 cells (Fig. 5b–c, both P < .001, Student’s t-test). Conversely, the knockdown of SLAIN2 reduced the number of migrated and invasive HCT-8 cells. (Fig. 5d–f, both P < .01, Student’s t-test). Moreover, in vivo assays verified that the ectopic expression or depletion of SLAIN2 increased or decreased the number of tumor colonies in the liver after injecting CRC cells into the tail vein of mice (Fig. 5g and h). Subsequently, the fluorescence recovery after photobleaching (FRAP) technique was employed to evaluate the speed of MT turnover to record the MT dynamics. GFP-α-tubulin and Lys-SLAIN or shSLAIN2 plasmids were co-transfected into CRC cells, resulting in stably expressed cell lines for the FRAP assay. The current data showed that the upregulation of SLAIN2 in SW480 cells promoted fluorescence recovery, including an increased mobile fraction and a decreased half-life after photobleaching, while the depletion of SLAIN2 in HCT-8 cells decreased the mobility and increased the half-life (Fig. 5i and j). Next, Western blot assay was used to measure the expression of the acetylated α-tubulin, a maker of MT stability. We found that acetylated α-tubulin was downregulated or upregulated after overexpression or knockdown of SLAIN2 in SW480 or HCT8 cells, respectively (Fig. 5k). Thus, these findings suggested that SLAIN2 facilitate the invasion and metastasis of CRC cells via regulation of the growth of MTs.

The above results indicated that MALAT1 regulated SLAIN2 expression via sponging miR-106b-5p in CRC cells. Whether MALAT1 could sponge miR-106b-5p and promote the invasion and metastasis of CRC cells through SLAIN2-mediated enhancement of MTs mobility needs further investigation. The FRAP assay discovered that ectopic expression of wild-type MALAT1, but not the mutant form MALAT1, promote fluorescence recovery, including an increased mobile fraction and a decreased half-life after photobleaching in SW480 cells, while co-transfecting miR-106b-5p mimics into SW480 cells partially attenuate these effects (Fig. 6a). Conversely, the depletion of MALAT1 resulted in decreasing mobility and increasing half-life after photobleaching. However, co-transfecting the miR-106b-5p inhibitors into MALAT1-depleted HCT8 cells could partially abolish these effects (Fig. 6b). The overexpression of wild-type MALAT1, but not the mutant MALAT1, downregulated the acetylated α-tubulin while co-transfecting the miR-106b-5p mimics into MALAT1-overexpressed SW480 cells partially attenuated these effects (Fig. 6c). Conversely, the suppression of MALAT1 upregulated the acetylated α-tubulin, which could be partially rescued by co-transfecting the miR-106b-5p inhibitors (Fig. 6d). Taken together, these data indicated that MALAT1 could regulate the MTs’ mobility in CRC cells via mediating the miR-106b-5p/SLAIN2 axis expression.

Next, the transwell assay also showed that the overexpression of wild-type MALAT1, but not the mutant MALAT1, resulted in increased migration and invasive numbers of SW480 cells, which can be partially abrogated by co-transfecting the miR-106b-5p mimics in SW480 cells (Fig. 6e and f; Fig. S5a and b). However, the knockdown of MALAT1 reduced the number of migrated and invasive HCT-8 cells, which could be partially reversed by co-transfecting the miR-106b-5p inhibitors (Fig. 6g and h; Fig. S5c and d). These data indicated that MALAT1 could promote the CRC cells’ migration and invasion by sponging miR-106b-5p in vitro.

To further confirm the epigenetic roles of MALAT1 on miR-106b-5p in vivo, the CRC cells were injected into tail vein of nude mice. Herein, we found that the overexpression of wild-type MALAT1 in SW480 cells, but not the mutant type, formed tumor colonies in the liver, while co-transfecting the miR-106b-5p mimics into SW480 partially reduced the colony number (Fig. 6i). Interestingly, the knockdown of wild-type MALAT1 in HCT-8 cells formed fewer tumor colonies in the liver, and these effects were reversed by co-transfecting the miR-106b-5p inhibitors (Fig. 6j). Thus, we revealed that MALAT1 promoted the CRC invasion and metastasis via sponging miR-106b-5p, and then regulated the SLAIN2-associated MT mobility.

**Fig. 4.** MALAT1 regulates the expression of SLAIN2 through competitive interaction with miR-106b-5p. (a) Potential targets of miR-106b-5p predicted with five miRNA target databases. (b) Schematic diagram of the luciferase reporter containing SLAIN2 3′UTR. Mutations were generated at the predicted miR-106b-5p-binding sites. (c) Roles of gradient concentration of miR-106b-5p inhibitor or mimics on the luciferase reporter activity with the wild-type SLAIN2 3′UTR. (d–e) Effects of miR-106b-5p overexpression or knockdown on luciferase reporter activity with the wild-type and mutated SLAIN2 3′UTR. (f–g) SLAIN2 RNA expression in miR-106b-5p-overexpressed SW480 and silenced HCT-8 cells. (h–i) SLAIN2 protein levels in the above cells. (j) MALAT1 and SLAIN2 share the same miRNA binding site. (k–l) Luciferase activity of SLAIN2 wild-type or mutated 3′UTR in SW480 cells co-transfected with MALAT1, MALAT1mut or MALAT1 + miR-106b-5p (k) and HCT-8 cells co-transfected with shNC, shMALAT1 or shMALAT1 + miR-106b-5p (l). (m–n) SLAIN2 RNA expression level in SW480 cells transfected with MALAT1mut or MALAT1 + miR-106b-5p (m) and HCT-8 cells transfected with shNC, shMALAT1 or shMALAT1 + miR-106b-5p (n). (o) Western blot analysis of SLAIN2 expression in the above cells. (p) Representative IHC staining of SLAIN2 in 95 CRC tissues, original magnification ×200; scale bar 100 μm. (q–r) The correlation analyses (Pearson’s correlation) of miR-106b-5p expression (q) or MALAT1 level (r) and SLAIN2 IHC scores in 95 CRC samples. Error bars denote s.d. of triplicates. *P < .05; **P < .01; ***P < .001, as means no significance. Student’s t-test.
2.6. High-level of MALAT1 is associated with CRC metastasis and predicts poor survival

TCGA dataset was used to analyze MALAT1 expression in CRC. We found that the MALAT1 expression in CRC tissues was higher than that in the normal tissues, and levels of MALAT1 in stage IV was higher than that in stage I-II (Fig. S6a and b). Similarly, MALAT1 expression was upregulated in CRC samples as compared to paired normal controls from the dataset of Shanghai General Hospital (Fig. 7a). Importantly, MALAT1 was much higher in stage III-IV or relapse group patients as compared to stage I-II or non-relapse group, respectively (Fig. 7b and c). Subsequently, we analyzed the correlations between MALAT1 expression and clinicopathological parameters in the 95 CRC patients. The relative MALAT1 expression in CRC was described as high or low based on the comparison to the paired normal tissues. Also, high MALAT1 expression was positively associated with lymph node metastasis and distant metastasis (Table S3).

Kaplan–Meier analysis with a log-rank test on tumor OS and RFS using TCGA dataset and our dataset showed that high MALAT1 resulted in poor OS and RFS in CRC patients (Fig. S6c and d; Fig. 7d and e). Moreover, high MALAT1 expression predicted poor OS in the relapse group but not in the non-relapse group (Fig. 7f and g). Thus, high MALAT1 is associated with CRC metastasis and predicted poor survival.

3. Discussion

Previously, the low expression of miR25 and miR93, the members of miR-106b~25 cluster family, has been demonstrated to promote the invasion and metastasis of colon cancer cells [5]. In this study, we verified that the level of another member of the cluster, miR-106b-5p was downregulated in CRC tissues, which in turn predicted poor prognosis for CRC patients. The downregulation of miR-106b-5p promoted the CRC cell invasion and metastasis in vitro and in vivo, which indicated the significant roles of miR-106b-5p in the development of CRC. Moreover, the present study also demonstrated that lncRNA MALAT1 sponges miR-106b-5p, followed by regulating the SLAIN2-associated MT mobility. The high risk of tumor recurrence and metastasis suggested that CRC patients with low miR-106b-5p expression and high MALAT1/SLAIN2 levels should receive an enhanced treatment postsurgery.
Even though increasing mechanisms concerning genetic and epigenetic alterations in CRC have been widely revealed, the survival rate of CRC patients is still poor [18]. Tumor recurrence and metastasis are ascribed for the poor survival of CRC patients after radical operation. Thus, identifying novel biomarkers that can efficiently predict the risks of tumor recurrence and metastasis might provide a better approach.

Fig. 6. MALAT1 sponges miR-106b-5p to promote the invasion and metastasis via SLAIN2-mediated enhanced MTs mobility. (a) FRAP assay analysis of mobility fraction and T₁/₂ (Time it took for half of the mobile fraction of microtubules to recover) in SW480 cells after transfected with MALAT1, MALAT1 mut or MALAT1 + miR-106b-5p. (b) Mobility fraction and T₁/₂ was measured with FRAP assay between the group treated with shNC, shMALAT1 and shMALAT1 + miR-106b-5p inhibitor in HCT-8 cells. (c–d) Western blot evaluated acetylated α-tubulin expression in MALAT1, MALAT1 mut or MALAT1 + miR-106b-5p transfected SW480 (c) and shNC, shMALAT1 and shMALAT1 + miR-106b-5p inhibitor treated HCT-8 cells (d). (e–f) Transwell assay analyzed the migratory and invasive abilities in MALAT1, MALAT1 mut or MALAT1 + miR-106b-5p transfected SW480 cells. (g–h) The changes of migratory and invasive abilities in shNC, shMALAT1 and shMALAT1 + miR-106b-5p inhibitor treated HCT-8 cells. (i–j) The number of liver metastatic lesions in nude mice injected with the above SW480 and HCT-8 cells via tail vein. Error bars in Fig. i–j denote s.d. of each group (5 mice). In remaining cases, error bars denote s.d. of triplicates. *P < .05; **P < .01; ***P < .001. P values were calculated with two-way ANOVA in left panel of a–b and Student’s t-test in other panels.
for an improved prognosis of CRC. Herein, we showed that miR-106b-5p acted as a repressor in CRC and high miR-106b-5p expression predicted an improved survival for CRC patients. These findings are consistent with the previous reports wherein miR-106b-5p was shown to function as a suppressor in papillary thyroid cancer and bladder cancer [19,20]. Reportedly, the miR-106b/25 cluster (consisting of miR-106b, miR-93, and miR-25) is localized on chromosome 7 (7q22.1) within intron 13 of the mini-chromosome maintenance gene, MCM7 that is transcriptionally activated by N-Myc. The MCM7 protein possesses the vital function of "licensing" the DNA synthesis during the transition from G1 to S phase [21,22]. Interestingly, miR-106b-5p promotes the aggressiveness and stem-cell-like phenotype of ccRCC cells by activating the Wnt/β-catenin signaling pathway [7]. Also, the upregulated level of miR-106b-5p prevents the p53 tumor suppressor activity, thereby enhancing the N-Myc pathway [8]. These dual roles as a tumor suppressor or oncogene indicated that miR-106b-5p might function in various cancers through different physiological behaviors. The investigation of ce-lncRNA provided insights into the mechanisms of dysregulation of miRNAs in CRC carcinogenesis and development to discover novel treatment approaches. Therefore, we hypothesized that endogenous lncRNAs regulated the miR-106b-5p expression in CRC.

The current bioinformatics analyses and luciferase reporter assays identified that MALAT1, a lncRNA, might be a potential ceRNA by sponging miR-106b-5p in CRC. These findings suggested that MALAT1 might promote the invasion and metastasis by regulating miR-106b-5p, which is in agreement with the previous findings [23–26]. In hepatocellular carcinoma, MALAT1 is upregulated and acts as a proto-oncogene via the activation of the Wnt pathway and induction of the oncogenic splicing factor SRSF [27]. The upregulation of the lncRNA MALAT1 also contributes to the proliferation and metastasis in esophageal squamous cell carcinoma [28]. In gastric cancer, MALAT1 could drive the development of cancer and promote peritoneal metastasis [23,29]. However, these findings were challenged by the study by Han et al., which showed that MALAT1 was functional as a tumor suppressor by attenuating the ERK/MAPK-mediated growth and MMP2-mediated invasiveness in glioma [30]. Thus, the different roles of MALAT1 were exerted on different tumors. The specific lncRNA was valuable in predicting the prognosis of CRC by investigating the correlations and between MALAT1 and miR-106b-5p.
High invasiveness and metastatic abilities are regarded as the main reasons for poor prognosis in malignant tumors [31]. In the present study, the overexpression of MALAT1 also promoted the invasion and metastasis of CRC cells in vitro and in vivo by sponging miR-106b-5p. Clinically, MALAT1 expression was negatively correlated with miR-106b-5p in CRC tissues. These findings were in agreement with those reported previously that MALAT1 enhanced the migration and invasiveness of CRC cells [25]. These results were similar to another study, wherein IncRNA NEAT1_2 regulated the expression of ATAD2 by sponging miR-106b-5p in papillary thyroid cancer and promoted the progression of bladder cancer [32]. Consequently, the current study verified that miR-106b-5p was sponged by MALAT1, which in turn, promoted the invasion and metastasis of CRC cells in vitro and in vivo.

Furthermore, onco-miRNAs functioned by downregulating the expression of the tumor suppressors in cancers [33]. The subsequent bioinformatics analyses and luciferase reporter assays demonstrated that SLAIN2 was the potential downstream target in CRC. It has been bioinformatics analyses and luciferase reporter assays demonstrated that SLAIN2 was the potential downstream target in CRC. It has been reported as an essential gene for mesenchymal cell invasion both in vitro and in the mouse tumor model via vesicle transport regulation [15]. As a key component of MT plus end interaction networks, SLAIN2 affects the MT activity and promotes the progression of bladder cancer [32]. Consequently, the current study verified that miR-106b-5p was sponged by MALAT1, which in turn, promoted the invasion and metastasis of CRC cells in vitro and in vivo.

4.1. Patient samples

A total of 95 CRC patients without preoperative anti-cancer treatment were enrolled in this study. All the cases were diagnosed pathologically and treated in Shanghai General Hospital during 2010. The patients with advanced-stage disease received standard postoperative 5-fluorouracil-based chemotherapy. The present study was approved by the Ethics Committee of Shanghai General Hospital and National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College.

4.2. Cell culture, overexpression, and RNA interference

Seven CRC cell lines (Caco2, HT-29, SW480, SW620, RKO, HCT-8, and LoVo) and one normal colon epithelial cell (NCM 460) were purchased from the Cell Bank of Chinese Academy of Sciences and cultured in DMEM medium with 10% fetal bovine serum (FBS, Gibco) in an incubator at 37 °C with 5% CO2. All the cell lines were authenticated through short tandem repeat analysis and used within 6 months. The last authentication was carried out in February 2018. The mimics and inhibitor of miR-106b-5p used to overexpress or knockdown the expression of miR-106b-5p were obtained from Ribobio (Guangzhou, China). The MALAT1, MALAT1-mut, shMALAT1 plasmids were synthesized by GenPharma (Shanghai, China). The plasmids and oligonucleotides were transfected into the cells using Lipofectamine 3000 (Invitrogen). The vectors with overexpression or knockdown of SLAIN2 were constructed and packaged as virus by GenPharma. SW480 cells stably expressing MALAT1, MALAT1-mut, or Lv-SLAIN2, and HCT-8 cells stably expressing shMALAT1 or shSLAIN2 were selected under puromycin antibiotic.

4.3. Cell migration and invasion assay

Transwell chambers (with inserts of 8-mm pore size) uncoated or coated with Matrigel were utilized for migration or invasion assay, respectively. Briefly, 1 × 105 cells were seeded in the upper chamber with FBS-free culture medium while the culture medium with 20% FBS was added in the bottom chamber. After 24 h incubation, the cells were fixed and stained with crystal violet.

4.4. In vivo experiment

10^5 CRC cells/mL in a 200 µL volume were injected into the tail veins of nude mice. Three weeks after injection, ultrasonography was used to monitor liver metastasis continuously for 8 weeks. Subsequently, all mice were sacrificed at 8 weeks, and the livers were retrieved for HE staining. The tumor colonies formed in the livers were observed and counted under a microscope. The experimental procedures were approved by the Animal Experiment Ethics Committee of the Cancer Hospital, Chinese Academy of Medical Sciences.

4.5. RNA extraction and quantitative PCR

The total RNA was extracted using TRIzol reagent (Invitrogen, CA, USA) and reverse transcribed using the PrimeScript RT reagent kit (TaKaRa, Dalian, China). Quantitative PCR was performed using SYBR Premix Ex Taq II (TaKaRa), and U6 or GAPDH was used as an internal control.

4.6. Protein extraction and western blot

Whole cell lysates were extracted using RIPA, separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to PVDF membranes. Subsequently, the membrane was probed with an acetylated α-tubulin antibody (1:1000), followed by incubation with secondary antibody and detected by chemiluminescence system.

4.7. HE staining, IHC, and FISH assays

For HE staining, paraffin-embedded tissues were dewaxed, rehydrated, HE stained, and dehydrated.

For IHC staining, after dewaxing and hydration, antigen retrieval was performed in EDTA. The tissues were stained with diaminobenzidine after sequential incubation with SLAIN2 antibody and secondary antibody as reported previously [34]. Then, the tissues were counterstained with hematoxylin and hydrated. The MALAT1 and miR-106B-5P oligodeoxynucleotide probes were obtained from Ribobio (Guangzhou, China). Moreover, FISH was performed as our reported previously [11].

4.8. RNA immunoprecipitation (RIP) assay

Cells were co-transfected with pMS2bp-GFP and MS2, MS2-MALAT1, or MS2-MALAT1 mut. After 48 h, RIP assay was performed using MEGA RIP™ Kit (Millipore) according to the manufacturer's instructions. The cell lysates were incubated with antibodies against GFP and IgG. After reverse transcription, the miR-106b-5p level was analyzed by qPCR.
For anti-AGO2 RIP, cells were transfected with miR-106b-5p mimics or miR-106b-5p inhibitor or controls for 48 h. Then, RIP assay was performed using AGO2 antibody. qPCR was performed to estimate the level of MALAT1 in RIP products.

4.9. RNA pull-down assay

Biotin-labeled miR-106b-5p and MALAT1 were synthesized by Genepharm and transfected into cells for 48 h. Then, the cells lysates were incubated with M-280 streptavidin magnetic beads (Sigma). TRIzol was used to purify the bound RNAs, and qPCR was employed to measure the level of MALAT1 or miR-106b-5p.

4.10. Luciferase reporter assay

The 3′-UTR of SLAIN2- or MALAT1-containing miR-106b-5p putative binding sites were amplified and cloned into a pGL3 vector. The mutation at the miR-106b-5p binding site was performed using a QuickChange Site-Directed Mutagenesis Kit (Stratagene). The cells were co-transfected with the wild-type or mutant luciferase vectors and miR-106b-5p, MALAT1, or the controls for 48 h. A dual-luciferase reporter gene assay system was utilized (Promega, Madison, WI, USA), and the relative luciferase activity was normalized to that of Renilla luciferase activity.

4.11. FRAP

Confocal laser-scanning microscopy was used for photobleaching for 10 s in cells stably expressing the GFP-labeled α-tubulin plasmid. At least 15 regions/sample were selected for bleaching and observed for 2 min to acquire the images every 2 s. The fraction of MTs that recovered within 2 min (mobility fraction), as well as the time required for half of the mobile fraction of MTs to recover (t1/2), was recorded. The recovered fluorescence intensities were normalized to that of the background and unbleached regions within the observed cells.

4.12. Bioinformatics analysis

The TCGA colorectal cancer RNAseq (Illumina HiSeq) dataset was used to compare the expression of miR-106b-5p or MALAT1 in normal and CRC tissues. Kaplan–Meier survival curves were drawn using the KMplot program (http://kmplot.com/analysis/).

4.13. Statistical analysis

SPSS 21.0 statistical software (SPSS Inc., Chicago, IL, USA) was applied for data analysis in this study. All in vitro assays were conducted for three biological and technical replicates. The data are represented as mean ± standard deviation (SD). P < .05 indicates statistical significance. Student’s t-test or one-way ANOVA was used to compare the continuous variables in two or multiple groups, respectively. Fisher’s exact test or chi-square test was applied to calculate the differences in the categorical variables. Correlations analyses were performed using Pearson’s or Spearman’s rank correlation test. RFS and OS were analyzed by Kaplan–Meier analysis with log-rank tests.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.12.049.

Acknowledgements

The authors wish to thank all the patients enrolled in this study. This work was supported by National Program Project for Precision Medicine in National Research and Development Plan of China (2016YFC0905300), National Natural Science Foundation of China (81572930), National Key Research and Development Program of the Ministry of Science and Technology of China (2016YFC0905303, 2016YFC1003200), Beijing Science and Technology Program (D17110002617004), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018PT32012), CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-12M-1-001), Incentive Fund for Academic Leaders of Oncology Hospital, Chinese Academy of Medical Sciences (RC2016003), and Beijing Hope Run Special Fund from Cancer Foundation of China (LC2017A19).

Declaration of interests

The authors declare no conflict of interest.

Author contributions

Meng Zhuang, Senlin Zhao, Zheng Jiang, Dongwang Yan, Xishan Wang conceived and designed the research study; Meng Zhuang, Senlin Zhao, Song Wang, Peng Sun, Jichuan Quan analyzed the data; Meng Zhuang, Senlin Zhao, Zheng Jiang, Dongwang Yan, Xishan Wang wrote and revised the manuscript. All authors read and approved the final manuscript.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics 2018;68(1):7–30.
[2] Brouwer NPM, Bos ACKR, Lemmens VEPP, et al. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer 2018 Aug 10. https://doi.org/10.1002/ijc.31785.
[3] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646–74.
[4] Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Invest 2017;127(3):761–71.
[5] Li Q, Zou C, Zou C, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett 2013;335(1):168–74.
[6] Zheng L, Zhang Y, Liu Y, et al. MiR-106b induces cell radiosensitivity via the PTEN/ PI3K/AKT pathways and p21 in colorectal cancer. J Transl Med 2015 Aug 4;13:252. https://doi.org/10.1186/s12967-015-0592-z.
[7] Jun Lu, Wei Jin-Huan, Feng Z-Hao, et al. miR-106b-5p promotes renal cell carcinoma aggressiveness and stem-cell-like phenotype by activating Wnt/β-catenin signaling. Oncotarget 2017;8(13):21461–71.
[8] Mastroppasqua F, Marzano F, Valletti A, et al. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Mol Cancer 2017;16(1):67. https://doi.org/10.1186/s12943-017-0634-7.
[9] Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell 2018;172(3):393–407.
[10] Ullitsky I, Shikumatawa A, Jan CH, Sive H, Bartel DP. Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell 2011;147(7):1537–50.
[11] Fang C, Qiu S, Sun F, et al. Long non-coding RNA HNF1A-AS1 mediates repression of miR-34a/SIRT1/p53 feedback loop promotes the metastatic progression of colon cancer by functioning as a competing endogenous RNA. Cancer Lett 2017;410:50–62.
[12] Chen P, Fang X, Xia B, Zhao Y, Li Q, Wu X. Long noncoding RNA LINC00152 promotes cell proliferation through competitively binding endogenous miR-125b with MCL-1 by regulating mitochondrial apoptosis pathways in ovarian cancer. Cancer Med 2018;7(9):4350–41.
[13] Qu L, Ding J, Chen C, et al. Exosome-transported IncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell 2016;29(5):653–68.
[14] Bose M, Barman B, Goswami A, Bhattacharyya SN. Spatiotemporal coupling of microRNA-mediated translational repression and target RNA degradation controls MicroRNP recycling in mammalian cells. Mol Cell Biol 2017;37(4):e00464-16.
[15] Bouchet BP, Noordstra I, van Amersfoort M, et al. Mesenchymal Cell Invasion Requires Cooperative Regulation of Persistent Microtubule Growth by SLAIN2 and CLASP1. Dev Cell 2016;39(6):708–23.
[16] Etienne-Manneville S. Microtubules in cell migration. Annu Rev Cell Dev Biol 2013;29:471
[17] Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147(5):992–1009.
[18] Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol 2015;33(16):96–9.
[19] Lee E, Collazo-Lorduy A, Castillo-Martin M, et al. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by actmir. Oncogene 2018. https://doi.org/10.1038/s41388-018-0367-0.
[20] Qian C, Yan W, Li T, et al. Differential expression of MiR-106b-5p and MiR-200c-3p in newly diagnosed versus chronic primary immune thrombocytopenia patients based on systematic analysis. Cell Physiol Biochem 2018;45(1):301–18.
[21] Koppen A, Ait-Aissa R, Koster J, et al. Direct regulation of the minichromosome maintenance complex by MYCN in neuroblastoma. Eur J Cancer 2007;43(16):2413–22.

[22] Shohet JM, Hicks MJ, Plon SE, et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002;62(4):1123–8.

[23] Yi Ren H, Ying Cong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer 2017;16(1):174.

[24] Chang SM, Hu WW. Long non-coding RNA MALAT1 promotes oral squamous cell carcinoma development via microRNA-125b/STAT3 axis. J Cell Physiol 2018;233(4):3384–96.

[25] Yang MH, Hu ZY, Xu C, et al. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim Biophys Acta 2015;1852(1):166–74.

[26] Kim SS, Harford JB, Moghe M, Rait A, Pirollo KF, Chang EH. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Nucleic Acids Res 2018;46(3):1424–40.

[27] Malakar P, Shilo A, Meglinsky A, et al. Long noncoding RNA MALAT1 promotes hepatocellular carcinoma development by SRSF1 upregulation and mTOR activation. Cancer Res 2017;77(5):1155–67.

[28] Hu L, Wu Y, Tan D, et al. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2015;34(7).

[29] Li L, Geng Y, Feng R, et al. The human RNA surveillance factor UPF1 modulates gastric cancer progression by targeting long non-coding RNA MALAT1. Cell Physiol Biochem 2017;42(6):2194–206.

[30] Han Y, Wu Z, Wu T, et al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/ MAPK signaling. Cell Death Dis 2016;7:e2123.

[31] Wilson K, Lewalle A, Fritzche M, Thorogate R, Duke T, Charras G. Mechanisms of leading edge protrusion in interstitial migration. Nat Commun 2013;4:2896.

[32] Sun W, Lan X, Zhang H, et al. NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis 2018;9(3):380.

[33] Bu P, Wang L, Chen KY, et al. miR-1269 promotes metastasis and forms a positive feedback loop with TGF-beta. Nat Commun 2015;6:6879.

[34] Zhao S, Jiang T, Tang H, et al. Ubiquitin D is an independent prognostic marker for survival in stage IIB–IIC colon cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. J Gastroenterol Hepatol 2015;30(4):680–8.